报价延迟最少15分钟:2026/09/19 15:19 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
4 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-2.42/-4.54
|
|
企业价值
113.76M
|
| 资产负债 |
|
每股账面净值
3.44
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
789.00K
|
|
每股收益
12.67
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Seres Therapeutics Inc is a clinical-stage biotechnology company focused on the development of live biotherapeutic candidates. Its pipeline includes candidates such as SER-155 and SER-603, aimed at preventing and treating bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases. The company operates as a single reportable segment, mainly developing microbiome-based therapies targeting bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases. |
